Siren, L.L.C. Phathom Pharmaceuticals, Inc. Transaction History
Siren, L.L.C.
- $2 Trillion
- Q3 2024
A detailed history of Siren, L.L.C. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 460,753 shares of PHAT stock, worth $4.49 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
460,753Holding current value
$4.49 Million% of portfolio
0.42%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
138Shares Held
67MCall Options Held
467KPut Options Held
49.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$98.6 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$72.8 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$57.2 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$39.9 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$34.1 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $382M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...